
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is focused on developing its lead product candidate, lanifibranor, as a potential treatment for non-alcoholic steatohepatitis (NASH), a significant unmet medical need, with evidence suggesting its benefits extend to high-risk subgroups such as those with Type 2 Diabetes. The positive impact of lanifibranor on metabolic markers and weight trajectory, alongside a potential role as a combination treatment option with other therapies, positions the company favorably within the evolving NASH therapeutic landscape. Additionally, management's optimistic outlook regarding lanifibranor's incremental benefits over existing treatments may enhance its market penetration and accelerate adoption, ultimately contributing to a stronger financial performance for Inventiva.
Bears say
Inventiva SA, a biopharmaceutical company focused on developing drugs for NASH and other conditions, reported a substantial net loss of €175.9 million, translating to €1.62 per share, which raises concerns about its financial stability. The company's primary clinical program, lanifibranor, is currently in Phase III development, and any efficacy or safety issues that arise could significantly negatively impact share performance. Additionally, high turnover in key regulatory positions, particularly the CEO and CMO, alongside dependence on research partnerships for revenue, presents further risks to the company’s operational continuity and future profitability.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares